We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Study Extends Potential of Personalized Cell-based Immunotherapies

News   Mar 16, 2018 | Original story from Ludwig Institute for Cancer Research

 
Study Extends Potential of Personalized Cell-based Immunotherapies

Shown here is a pseudo-colored scanning electron micrograph of an oral squamous cancer cell (white) being attacked by two cytotoxic T cells (red), part of a natural immune response. Credit: Rita Elena Serda, NCI/Duncan Comprehensive Cancer Center at Baylor College of Medicine

 
 
 

RELATED ARTICLES

New Regulators of Macrophage Pyroptosis

News

Two enzymes, TAK1 and IKK, have been identified as important kinases involved in the regulation of pyroptosis - a highly inflammatory form of programmed cell death, which often forms part of the antimicrobial response.

READ MORE

Statins Have Low Risk of Side Effects

News

The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients. Since statins are associated with a low risk of side effects, the benefits of taking them outweigh the risks, according to a scientific statement from the American Heart Association that reviewed multiple studies evaluating the safety and potential side effects of these drugs.

READ MORE

Deciphering Mechanisms of Childhood Tumor Growth & Regression

News

Researchers from Charité - Universitätsmedizin Berlin have studied the genetic factors behind different tumor subtypes and their prognoses. Their findings enable clinicians to predict the precise clinical course of the disease, and to adapt their treatment regimens accordingly.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma Cancer Research Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE